The myeloid response to pancreatic carcinogenesis is regulated by the receptor for advanced glycation end-products

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Pancreatic cancer is a deadly disease with complex immune microenvironments.
• Myeloid-derived suppressor cells (MDSCs) are key players in tumor immune evasion.
• The role of specific receptors in regulating MDSC accumulation during carcinogenesis is not fully understood.

Purpose of the Study:

• To investigate the role of the receptor for advanced glycation end products (RAGE) in pancreatic carcinogenesis.
• To determine how RAGE influences the accumulation of MDSCs within the tumor microenvironment.
• To explore the impact of RAGE on other myeloid cell populations during tumor development.

Main Methods:

• Utilized a mouse model with an oncogenic Kras variant to study pancreatic carcinogenesis.
• Assessed the effect of RAGE absence on tumor development and progression.
• Quantified the accumulation of MDSCs and other myeloid cells (macrophages) in the tumor microenvironment.
• Analyzed the immunosuppressive capacity of accumulated myeloid cells.

Main Results:

• Absence of RAGE significantly delayed pancreatic neoplasia in mice.
• RAGE deficiency markedly reduced the accumulation of MDSCs within tumors.
• Mice lacking RAGE accumulated non-immunosuppressive macrophages instead of MDSCs.
• RAGE plays a critical role in regulating myeloid cell responses during pancreatic carcinogenesis.

Conclusions:

• RAGE is a critical regulator of MDSC accumulation in pancreatic cancer.
• Targeting RAGE may offer a novel therapeutic strategy to overcome immune suppression in pancreatic cancer.
• RAGE influences the balance of myeloid cell populations, impacting tumor progression.